According to several foreign media websites, a source who declined to be identified said that Thermo Fisher had proposed a $30 billion takeover offer to illumina.

Affected by this, Illumina shares rose 1.9% throughout the day on August 18 (US Eastern Time) to close at 172.37 US dollars, once reached an intraday high of 182.67 US dollars. However, Doug Schenkel, an analyst at market research firm Cowen and Co, said: The probability of success in this acquisition is basically zero. At present, Illumina has a market value of $25.2 billion, and Thermo Fisher's 30 billion offer is obviously not much for Illumina. Attractive.

Earlier in 2012, Illumina shareholders had rejected Roche's $6.7 billion takeover offer, bluntly quoting too low.

Another industry insider said that the gene sequencing industry is in a booming stage and has a good vision for the future. Illumina, as the leading upstream supplier of the entire gene sequencing industry, does not need to accept the offer.

In 2013, Thermo Fisher took $13.6 billion to acquire Life Technologies and entered the field of gene sequencers. Its Ion Torrent is also one of the current competitors in the field of genetic sequencers, but the entire genetic sequencer market is still dominated by Illumina. On July 26, Illumina's Q2 earnings report showed that the company's second-quarter revenue increased by 11%. Revenue reached $601 million.

Thermo Fisher may wish to further strengthen its layout in the field of sequencer and even genetic diagnosis through acquisition, and connect with its diagnostic business, analytical instruments and other businesses to create a more competitive overall business solution.

However, at present, if you want to realize the acquisition of Illumina, I am afraid it will take more trouble.

Lower Blood Pressure Plant Extract

Lower Blood Pressure Plant Extract,Nattokinase Powder,Nattokinase Extract,Nattokinase Extract For Cardiovascular

Fufeng Sinuote Biotechnology Co.,Ltd. , https://www.sinuotebio.com